Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by GunnerGon May 12, 2020 7:45pm
72 Views
Post# 31019815

RE:RE:RE:Expected ER date according to Bloomberg

RE:RE:RE:Expected ER date according to Bloomberg LMNL is considered venture so they must report by June 1, 2020.

TSX FS filing requirements.



aldo451 wrote: I doubt that is correct. From TMX site; 

Quarterly financial statements and interim MD&A2 • Within 45 days of the end of 1 st, 2nd and 3rd financial quarter • 


<< Previous
Bullboard Posts
Next >>